Cargando…

Immunogenicity and protective efficacy of GBP510/AS03 vaccine against SARS-CoV-2 delta challenge in rhesus macaques

Despite the availability of several effective SARS-CoV-2 vaccines, additional vaccines will be required for optimal global vaccination. In this study, we investigate the immunogenicity and protective efficacy of the GBP510 protein subunit vaccine adjuvanted with AS03, which has recently been authori...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacob-Dolan, Catherine, Yu, Jingyou, McMahan, Katherine, Giffin, Victoria, Chandrashekar, Abishek, Martinot, Amanda J., Anioke, Tochi, Powers, Olivia C., Hall, Kevin, Hope, David, Miller, Jessica, Hachmann, Nichole P., Chung, Benjamin, Gardner, Sarah, Sellers, Daniel, Barrett, Julia, Lewis, Mark G., Andersen, Hanne, Kleanthous, Harry, Seo, Ki-Woen, Lee, Su Jeen, Park, Yong Wook, Kim, Hun, Barouch, Dan H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947939/
https://www.ncbi.nlm.nih.gov/pubmed/36823160
http://dx.doi.org/10.1038/s41541-023-00622-0
_version_ 1784892670436442112
author Jacob-Dolan, Catherine
Yu, Jingyou
McMahan, Katherine
Giffin, Victoria
Chandrashekar, Abishek
Martinot, Amanda J.
Anioke, Tochi
Powers, Olivia C.
Hall, Kevin
Hope, David
Miller, Jessica
Hachmann, Nichole P.
Chung, Benjamin
Gardner, Sarah
Sellers, Daniel
Barrett, Julia
Lewis, Mark G.
Andersen, Hanne
Kleanthous, Harry
Seo, Ki-Woen
Lee, Su Jeen
Park, Yong Wook
Kim, Hun
Barouch, Dan H.
author_facet Jacob-Dolan, Catherine
Yu, Jingyou
McMahan, Katherine
Giffin, Victoria
Chandrashekar, Abishek
Martinot, Amanda J.
Anioke, Tochi
Powers, Olivia C.
Hall, Kevin
Hope, David
Miller, Jessica
Hachmann, Nichole P.
Chung, Benjamin
Gardner, Sarah
Sellers, Daniel
Barrett, Julia
Lewis, Mark G.
Andersen, Hanne
Kleanthous, Harry
Seo, Ki-Woen
Lee, Su Jeen
Park, Yong Wook
Kim, Hun
Barouch, Dan H.
author_sort Jacob-Dolan, Catherine
collection PubMed
description Despite the availability of several effective SARS-CoV-2 vaccines, additional vaccines will be required for optimal global vaccination. In this study, we investigate the immunogenicity and protective efficacy of the GBP510 protein subunit vaccine adjuvanted with AS03, which has recently been authorized for marketing in South Korea under the trade name SKYCovione(TM). The antigen in GBP510/AS03 is a two-part recombinant nanoparticle, which displays 60 receptor binding domain (RBD) proteins of SARS-CoV-2 Spike on its surface. In this study we show that GBP510/AS03 induced robust immune responses in rhesus macaques and protected against a high-dose SARS-CoV-2 Delta challenge. We vaccinated macaques with two or three doses of GBP510/AS03 matched to the ancestral Wuhan strain of SARS-CoV-2 or with two doses of GBP510/AS03 matched to the ancestral strain and one dose matched to the Beta strain. Following the challenge with Delta, the vaccinated macaques rapidly controlled the virus in bronchoalveolar lavage and nasal swabs. Binding and neutralizing antibody responses prior to challenge correlated with protection against viral replication postchallenge. These data are consistent with data with this vaccine from the phase 3 clinical trial.
format Online
Article
Text
id pubmed-9947939
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-99479392023-02-23 Immunogenicity and protective efficacy of GBP510/AS03 vaccine against SARS-CoV-2 delta challenge in rhesus macaques Jacob-Dolan, Catherine Yu, Jingyou McMahan, Katherine Giffin, Victoria Chandrashekar, Abishek Martinot, Amanda J. Anioke, Tochi Powers, Olivia C. Hall, Kevin Hope, David Miller, Jessica Hachmann, Nichole P. Chung, Benjamin Gardner, Sarah Sellers, Daniel Barrett, Julia Lewis, Mark G. Andersen, Hanne Kleanthous, Harry Seo, Ki-Woen Lee, Su Jeen Park, Yong Wook Kim, Hun Barouch, Dan H. NPJ Vaccines Article Despite the availability of several effective SARS-CoV-2 vaccines, additional vaccines will be required for optimal global vaccination. In this study, we investigate the immunogenicity and protective efficacy of the GBP510 protein subunit vaccine adjuvanted with AS03, which has recently been authorized for marketing in South Korea under the trade name SKYCovione(TM). The antigen in GBP510/AS03 is a two-part recombinant nanoparticle, which displays 60 receptor binding domain (RBD) proteins of SARS-CoV-2 Spike on its surface. In this study we show that GBP510/AS03 induced robust immune responses in rhesus macaques and protected against a high-dose SARS-CoV-2 Delta challenge. We vaccinated macaques with two or three doses of GBP510/AS03 matched to the ancestral Wuhan strain of SARS-CoV-2 or with two doses of GBP510/AS03 matched to the ancestral strain and one dose matched to the Beta strain. Following the challenge with Delta, the vaccinated macaques rapidly controlled the virus in bronchoalveolar lavage and nasal swabs. Binding and neutralizing antibody responses prior to challenge correlated with protection against viral replication postchallenge. These data are consistent with data with this vaccine from the phase 3 clinical trial. Nature Publishing Group UK 2023-02-23 /pmc/articles/PMC9947939/ /pubmed/36823160 http://dx.doi.org/10.1038/s41541-023-00622-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Jacob-Dolan, Catherine
Yu, Jingyou
McMahan, Katherine
Giffin, Victoria
Chandrashekar, Abishek
Martinot, Amanda J.
Anioke, Tochi
Powers, Olivia C.
Hall, Kevin
Hope, David
Miller, Jessica
Hachmann, Nichole P.
Chung, Benjamin
Gardner, Sarah
Sellers, Daniel
Barrett, Julia
Lewis, Mark G.
Andersen, Hanne
Kleanthous, Harry
Seo, Ki-Woen
Lee, Su Jeen
Park, Yong Wook
Kim, Hun
Barouch, Dan H.
Immunogenicity and protective efficacy of GBP510/AS03 vaccine against SARS-CoV-2 delta challenge in rhesus macaques
title Immunogenicity and protective efficacy of GBP510/AS03 vaccine against SARS-CoV-2 delta challenge in rhesus macaques
title_full Immunogenicity and protective efficacy of GBP510/AS03 vaccine against SARS-CoV-2 delta challenge in rhesus macaques
title_fullStr Immunogenicity and protective efficacy of GBP510/AS03 vaccine against SARS-CoV-2 delta challenge in rhesus macaques
title_full_unstemmed Immunogenicity and protective efficacy of GBP510/AS03 vaccine against SARS-CoV-2 delta challenge in rhesus macaques
title_short Immunogenicity and protective efficacy of GBP510/AS03 vaccine against SARS-CoV-2 delta challenge in rhesus macaques
title_sort immunogenicity and protective efficacy of gbp510/as03 vaccine against sars-cov-2 delta challenge in rhesus macaques
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947939/
https://www.ncbi.nlm.nih.gov/pubmed/36823160
http://dx.doi.org/10.1038/s41541-023-00622-0
work_keys_str_mv AT jacobdolancatherine immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques
AT yujingyou immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques
AT mcmahankatherine immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques
AT giffinvictoria immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques
AT chandrashekarabishek immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques
AT martinotamandaj immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques
AT anioketochi immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques
AT powersoliviac immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques
AT hallkevin immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques
AT hopedavid immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques
AT millerjessica immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques
AT hachmannnicholep immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques
AT chungbenjamin immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques
AT gardnersarah immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques
AT sellersdaniel immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques
AT barrettjulia immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques
AT lewismarkg immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques
AT andersenhanne immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques
AT kleanthousharry immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques
AT seokiwoen immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques
AT leesujeen immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques
AT parkyongwook immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques
AT kimhun immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques
AT barouchdanh immunogenicityandprotectiveefficacyofgbp510as03vaccineagainstsarscov2deltachallengeinrhesusmacaques